Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
CureVac AG manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 5 pending office actions currently active across this portfolio. These actions are distributed among 5 distinct examiners, which represents a high level of examiner diversity for the applicant.
POHNERT, STEVEN C is identified as the busiest examiner, currently overseeing 1 pending office action. This indicates that the pending office actions are spread evenly, with no individual examiner handling more than a single case. For a practitioner, this means that prosecution strategies must be independently developed for the various individuals involved.
The involvement of 5 distinct art units suggests that the pending patents cover a broad range of technical subjects within the Biotechnology & Pharmaceuticals field. Because the busiest examiner pending count is 1, there is no concentration of influence by any single examiner over the portfolio. Each of the pending office actions requires a unique approach tailored to the specific art unit assigned.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | FAY, ZOHREH ALEMZADEH | 73d overdue |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | LEITH, NANCY J | 30d |
| 17820559 | METHOD FOR IN VITRO TRANSCRIPTION USING AN IMMOBILIZED RESTRICTION ENZYME | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | WILSON, MICHAEL C | 81d overdue |
| 17620047 | ROTAVIRUS MRNA VACCINE | GRABER, JAMES J | 8d overdue |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | LEITH, NANCY J | 30d |
| 17820559 | METHOD FOR IN VITRO TRANSCRIPTION USING AN IMMOBILIZED RESTRICTION ENZYME | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1636 | 1 |
| 1631 | 1 |
| 1617 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17820559 | METHOD FOR IN VITRO TRANSCRIPTION USING AN IMMOBILIZED RESTRICTION ENZYME | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | Aug 17, 2022 |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | LEITH, NANCY J | 1636 | §101§103§112Other | Non-Final OA | 30d | Pending | Jan 14, 2022 |
| 17620047 | ROTAVIRUS MRNA VACCINE | GRABER, JAMES J | 1631 | §103DP | Final Rejection | 8d overdue | Pending | Dec 16, 2021 |
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Final Rejection | 73d overdue | Pending | Aug 06, 2021 |
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | WILSON, MICHAEL C | 1638 | §103 | Non-Final OA | 81d overdue | Pending | Jul 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCureVac AG has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Steven C Pohnert has the most, with 1 of CureVac AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
